Pharmacogenomic Evaluation of Antihypertensive Responses 2

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Collaborator: National Institute of General Medical Sciences (NIGMS)
• Treatments: Antihypertensive Agents; Chlorthalidone; Metoprolol

Criteria

Inclusion Criteria:

• An average seated home diastolic blood pressure (DBP) > 85 mmHg and < 110 mmHg and home systolic blood pressure (SBP) < 180 mmHg.

• Subjects must also have an average seated (> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP < 180 mmHg

Exclusion Criteria:

• Secondary forms of hypertension (HTN) (including sleep apnea)

• Isolated systolic HTN

• Other diseases requiring treatment with BP lowering medications

• Heart rate < 55 beats/min (for metoprolol only)

• Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA)

• Diabetes mellitus (Type 1 or 2)

• Renal insufficiency (serum creatinine > 1.5 in men or 1.4 in women)

• Primary renal disease

• Pregnancy or lactation

• Liver enzymes > 2.5 upper limits of normal

• Current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.